Eli Lilly Balance Sheet Health
Financial Health criteria checks 1/6
Eli Lilly has a total shareholder equity of $10.9B and total debt of $25.4B, which brings its debt-to-equity ratio to 233.4%. Its total assets and total liabilities are $64.0B and $53.1B respectively. Eli Lilly's EBIT is $10.8B making its interest coverage ratio 34.5. It has cash and short-term investments of $3.0B.
Key information
233.4%
Debt to equity ratio
US$25.36b
Debt
| Interest coverage ratio | 34.5x |
| Cash | US$3.04b |
| Equity | US$10.86b |
| Total liabilities | US$53.14b |
| Total assets | US$64.01b |
Recent financial health updates
Eli Lilly (NYSE:LLY) Has A Pretty Healthy Balance Sheet
Dec 05
Is Eli Lilly (NYSE:LLY) Using Too Much Debt?
Aug 24Recent updates
Wall Street Lunch: Lilly In Limelight
Apr 17Eli Lilly: Diabetes And Weight Management Treatments Are The Winning Tickets
Mar 29Eli Lilly: The Party Is Not Over
Mar 23Estimating The Intrinsic Value Of Eli Lilly and Company (NYSE:LLY)
Mar 17Eli Lilly: Yes, It Is Too Late To Join The Party
Feb 20Eli Lilly: Overvaluation Is A Big Red Flag
Feb 14Eli Lilly and Company: Even 'Miracle Drugs' Can't Keep Stock Rising (Downgrade)
Feb 07Eli Lilly: GLP-1's Potential In More Indications Should Unlock Significant Value
Jan 31Eli Lilly (NYSE:LLY) Has Announced That It Will Be Increasing Its Dividend To $1.30
Jan 24Eli Lilly: The Cupboard Is Fully Stocked
Jan 19Eli Lilly: The Buzz Is Not Over
Jan 11Eli Lilly (NYSE:LLY) Is Increasing Its Dividend To $1.30
Jan 10Eli Lilly (NYSE:LLY) Is Paying Out A Larger Dividend Than Last Year
Dec 27Pinning Down Eli Lilly and Company's (NYSE:LLY) P/S Is Difficult Right Now
Dec 24Eli Lilly: Long Path To A Trillion
Dec 21Eli Lilly (NYSE:LLY) Has A Pretty Healthy Balance Sheet
Dec 05Bubble Warning: Unrealistic Growth Priced In And Multiple Risk Factors For Eli Lilly
Nov 30Eli Lilly: Perfectly Priced Healthcare Giant
Nov 16Eli Lilly: Zepbound For Weight Loss FDA Approved - Time To Believe The Hype?
Nov 09Calculating The Intrinsic Value Of Eli Lilly and Company (NYSE:LLY)
Oct 30Eli Lilly: The GLP-1 Opportunity, While Increasingly Recognized, Is Vastly Underestimated
Oct 11Eli Lilly: Big Cancer Bet With Point Biopharma Global Purchase
Oct 05Eli Lilly: Don't Be Fooled By Greed
Sep 20Eli Lilly Stock Hits New All-Time Highs: Is It Still A Buy?
Sep 11Here's Why We Think Eli Lilly (NYSE:LLY) Is Well Worth Watching
Sep 11Is Eli Lilly (NYSE:LLY) Using Too Much Debt?
Aug 24Sell Eli Lilly And Buy This Coiled-Spring Dividend Aristocrat Instead
Aug 23Eli Lilly Q2: Dividends Don't Lie
Aug 14Eli Lilly Remains A Buy With Strong Sales And Possible Upside With Mounjaro
Aug 08Financial Position Analysis
Short Term Liabilities: LLY's short term assets ($25.7B) do not cover its short term liabilities ($27.3B).
Long Term Liabilities: LLY's short term assets ($25.7B) do not cover its long term liabilities ($25.8B).
Debt to Equity History and Analysis
Debt Level: LLY's net debt to equity ratio (205.4%) is considered high.
Reducing Debt: LLY's debt to equity ratio has increased from 95.1% to 233.4% over the past 5 years.
Debt Coverage: LLY's debt is not well covered by operating cash flow (16.7%).
Interest Coverage: LLY's interest payments on its debt are well covered by EBIT (34.5x coverage).